Market Currents
Abbott Laboratories' (ABT) AbbVie spin-off is worth more than Abbott ahead of the official split...
-
Tuesday, December 11, 2012, 4:06 AM ETAbbott Laboratories' (ABT) AbbVie spin-off is worth more than Abbott ahead of the official split of the company in January. "When issued" trading in the two entities began yesterday in the secondary market, with the new Abbott valued at $47.9B and AbbVie $55.3B. The market cap of the combined Abbott is $103.27B.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
This news story has 5 comments:
Abbott Park, Illinois (NYSE: ABT) — Abbott announced today that its board of directors has approved the separation of its research-based pharmaceuticals business, which will be known as AbbVie Inc., and declared a special dividend distribution of all of the outstanding shares of AbbVie common stock.
For every 1 share of Abbott common shares held, Abbott shareholders will receive 1 share of AbbVie common stock. No fractional shares of AbbVie will be issued. Shareholders will receive cash in lieu of fractional shares. The special dividend distribution is expected to be paid on Jan. 1, 2013, to Abbott shareholders of record as of the close of business on Dec. 12, 2012.